venetoclax,blinatumomab
amgen,roche,astellas,abbvie,intensity therapeutics
['aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'blinatumomab', 'venetoclax', 'intensity thera']
#ash22 venetoclax with low dose ara-c (valdac study) is highly effective in aml with (predominantly npm1) mrd or early morphologic relapse: mrd response 69% (mrd neg 54%); cr/cri 77%; favorable toxicity profile. 